Earlier this month, Korro Bio announced a collaboration with Novo Nordisk (NYSE:NVO) to develop a pair of therapeutic ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Some other companies using ADAR enzymes to perform RNA editing are Korro Bio for AATD and Parkinson’s disease ... from large ...

Shares in Novo Nordisk A/S (DK:NOVO.B) have lost a fifth of their market value since the end of June, the point at which the Danish pharma group revealed that it was committing around $4bn (£3.2bn) to ...

Eli Lilly (NYSE:LLY) is reportedly preparing to launch its drug Mounjaro in Denmark, the home country of its leading rival in the weight-loss drug market, Novo Nordisk (NVO). Lilly (LLY ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes ...

Denmark unveiled an Nvidia-powered supercomputer that will be used by researchers from Novo Nordisk A/S and other Danish pharmaceutical companies as they seek novel drugs and smarter trial designs ...

Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic.

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...

RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...